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Abstract
Background: Delays in diagnosis and treatment of tuberculosis (TB) remain common in high-burden countries. To
improve case detection, substantial investments have been made to scale-up Xpert MTB/RIF (Xpert), a cartridge-
based nucleic acid amplification test that can detect TB within 2 hours, as a replacement for sputum smear
microscopy. However, the optimal strategy for implementation of Xpert testing remains unclear.
Methods: The Xpert Performance Evaluation for Linkage to Tuberculosis Care (XPEL-TB) trial uses an ultra-pragmatic,
hybrid type II effectiveness-implementation design to assess the effectiveness and implementation of a streamlined
strategy for delivery of Xpert testing in real-world settings. Twenty health centers with TB microscopy units were
selected to participate in the trial, with ten health centers randomized to the intervention strategy (onsite molecular
testing using GeneXpert Edge, process redesign to facilitate same-day TB diagnosis and treatment, and performance
feedback) or routine care (onsite sputum smear microscopy plus referral of sputum samples to Xpert testing sites). The
primary outcome is the number of patients with microbiologically confirmed TB who were initiated on treatment
within 14 days of presentation to the health center, which reflects successful completion of the TB diagnostic
evaluation process. Secondary outcomes include health outcomes (6-month vital status), as well as measures of the
reach, adoption, and implementation of the intervention strategy.
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Discussion: The design elements and implementation approach for the XPEL-TB trial were intentionally selected to
minimize disruptions to routine care procedures, with the goal of limiting their influence on key primary and secondary
outcomes. Trial findings may result in increased support and funding for rapid, onsite molecular testing as the
standard-of-care for all patients being evaluated for TB.
Trial registration: US National Institutes of Health’s ClinicalTrials.gov, NCT03044158. Registered 06 February 2017.
Pan African Clinical Trials Registry, PACTR201610001763265. Registered 03 September 2016.
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Background
Early detection and treatment of tuberculosis (TB) are
critical for reducing TB-related mortality and disease
transmission. However, delayed and missed TB diagno-
ses remain pervasive in high-burden TB countries.
Mathematical modeling suggests that an accessible rapid
test with > 85% sensitivity and 97% specificity could
avert between 12.3 and 22.4% of annual TB deaths, de-
pending on rates of loss to follow-up [1]. Xpert MTB/
RIF (Xpert) (Cepheid, Sunnyvale, CA, USA), a semi-
automated, cartridge-based nucleic acid amplification
test that can detect Mycobacterium tuberculosis and ri-
fampicin resistance within 2 hours, is the first rapid TB
test to approach these performance criteria. Since its en-
dorsement as a replacement for smear microscopy by
the World Health Organization in 2010, considerable
global investment has been made to scale up Xpert test-
ing capacity in high-burden countries. By the end of
2016, > 6500 GeneXpert modules and > 23 million
Xpert cartridges had been procured by 130 countries
with access to concessional pricing [2, 3]. However, the
optimal strategy for implementing Xpert testing in high
burden countries remains unknown.
High costs and infrastructure requirements restricted
placement of the first generation of GeneXpert devices
to higher-level facilities used by less than 15% of the
population [4]. To increase access to Xpert testing, many
high-burden countries have established specimen refer-
ral networks linking lower-level health facilities (spokes)
to health facilities equipped with GeneXpert devices
(hubs) [5–8]. However, studies have documented persist-
ent challenges to the TB diagnostic evaluation process,
including low utilization of Xpert, delays between spu-
tum collection and return of Xpert results, and high
rates of pre-treatment loss to follow-up for Xpert-
positive patients [9–11].
The next generation of molecular diagnostics has been
specifically designed for lower-level health centers, and
thus has the potential to close these gaps in the TB diag-
nostic evaluation cascade of care. GeneXpert Edge is a
battery-operated, single-module device equipped with
cooling fans and dust filters and operated using a
touchscreen tablet. Compared to the previous generation
of GeneXpert devices, GeneXpert Edge is more durable,
less costly, and designed to overcome limitations of
resource-constrained settings, such as instability of the
power supply and vulnerability to dust, heat, and humid-
ity. These features have enhanced the potential of onsite
Xpert testing as a viable alternative to sputum smear mi-
croscopy at lower-level health centers.
This paper describes the design of the GeneXpert Per-
formance Evaluation for Linkage to Tuberculosis Care
(XPEL-TB) trial, which seeks to evaluate streamlined TB
diagnostic evaluation using onsite, rapid molecular TB
testing. The scientific rationale for the proposed imple-
mentation strategy (referred to hereafter as “intervention
strategy”) builds on work from a previous study by ad-
dressing key barriers to TB diagnostic evaluation at
community health centers [12]. The aims of the XPEL-
TB trial are to (1) compare the completion of TB diag-
nostic evaluation at community health centers (clusters)
randomized to the intervention vs. routine TB diagnostic
evaluation strategies, (2) identify processes and context-
ual factors that influence the implementation of the
intervention strategy, and (3) compare the costs and
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 Trial design and execution may impact routine care
procedures, making it harder to determine whether an
intervention will improve patient- and public health-
important outcomes when implemented in a real-world
context.
 This paper describes the design and execution of an ultra-
pragmatic trial to assess the effectiveness and implementa-
tion of a streamlined TB diagnostic strategy based around
rapid, onsite molecular testing. Pragmatic design elements
are emphasized.
 Trialists may find this paper a helpful roadmap to adopt a
more pragmatic approach to study design and
implementation in a global health context.
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epidemiological impact of the intervention vs. routine
TB diagnostic evaluation strategies at all trial sites.
Methods/design
Study setting
The XPEL-TB trial is being conducted at 20 community
health centers across the four administrative regions of
Uganda to assess the effectiveness and implementation
of the intervention in a mix of urban, peri-urban, and
rural contexts. Uganda was selected as the trial setting
for its high rates of TB and HIV/TB co-infection, with
an estimated 86,000 TB cases and 34,000 HIV/TB cases
in 2017 [13]. Uganda has been a regional leader in scal-
ing up Xpert testing [2], and current Uganda National
Tuberculosis and Leprosy Programme (NTLP) guide-
lines recommend Xpert as the first-line test for active
pulmonary TB at health centers equipped with a GeneX-
pert device. At other health centers, including most
community health centers, the guidelines recommend
sputum smear microscopy as the initial test, followed by
referral-based Xpert testing for smear-negative patients
who have strong risk factors for TB (e.g., HIV infection)
or a high clinical probability of TB after re-evaluation [14].
Trial design
The XPEL-TB trial is an ultra-pragmatic, parallel cluster-
randomized trial, with a hybrid type II effectiveness-
implementation design [15]. An ultra-pragmatic approach,
one in which all trial design elements included in the
Pragmatic-Explanatory Continuum Indicator Summary 2
(PRECIS-2) tool are oriented toward evaluating the inter-
vention strategy as it would be implemented in actual
practice (i.e., towards the pragmatic end of the pragmatic-
explanatory continuum), was selected to maximize applic-
ability of results and to minimize interference with routine
care [16]. The units of randomization and analysis (clus-
ters) are community health centers that are part of Xpert
referral networks in Uganda, with 10 sites per trial arm.
Clusters rather than individual patients were randomized
due to pragmatic feasibility, as well as concerns about con-
tamination. Nested studies employing mixed-methods,
health economics, and modeling methodologies are in-
cluded in the trial in order to assess the implementation,
cost-effectiveness, and epidemiological impact of the
intervention strategy.
Target setting and study sample
Site- and individual-level eligibility criteria are restricted
to those that represent the real-world settings and pa-
tient populations receiving the intervention outside of a
trial context. The ideal setting for onsite Xpert testing is
the point of care nearest to the largest number of pa-
tients seeking care for TB symptoms (i.e., the lowest
level of the health system); in Uganda, these are level III
and level IV community health centers with TB micros-
copy units. Additional site-level inclusion criteria include
the use of sputum smear microscopy as the primary
method of TB diagnosis, participation in NTLP-sponsored
external quality assurance for sputum smear microscopy,
and linkage to a district or regional hospital for referral of
samples for Xpert testing. For feasibility purposes, trial in-
clusion was also limited to health centers located within
150miles of Kampala, as well as those that evaluated at
least 150 patients for pulmonary TB and diagnosed a
minimum of 15 smear-positive patients annually accord-
ing to 2015 NTLP reporting data.
At the individual level, all adults (18+) who are evalu-
ated for pulmonary TB at study sites (aim 1) during the
trial period are included. Patients already diagnosed with
TB (i.e., referred for treatment after being diagnosed
elsewhere or already on TB treatment) or with a docu-
mented prior history of TB (due to concerns about false-
positive Xpert results in this population) are excluded
[17]. Surveys, direct observation studies, interviews, and/
or focus group discussions (aims 2 and 3) are conducted
in a subset of patients and providers involved in TB
diagnosis and/or treatment at study sites.
Informed consent
To ensure the trial captures complete data on all adults
undergoing TB evaluation at study sites, a waiver of indi-
vidual informed consent was obtained to extract patient-
level data from Uganda NTLP TB registers used rou-
tinely by health facilities to record TB screening, testing,
and treatment data. The waiver was justified on grounds
that the intervention strategy poses no more than min-
imal risk to patients because it does not involve add-
itional specimen collection and facilitates more rapid
access to Xpert testing than would occur in routine care.
However, informed consent is obtained from patients
and providers who participate in surveys, direct observa-
tion studies, interviews, and/or focus group discussions
related to the implementation and costing sub-studies.
Intervention strategy
The theory-informed intervention strategy targets modi-
fiable barriers of adherence to guidelines for TB diagnos-
tic evaluation identified during formative work (Fig. 1)
[12]. The Theory of Planned Behavior, which states that
intention—mediated by knowledge, attitudes, subjective
norms, and self-efficacy—predicts behavior (i.e., guide-
line adherence) [18] served as the conceptual model that
informed the intervention strategy. The conceptual
model also incorporated health system (financial and hu-
man resources, coordination of services, and service im-
plementation) and patient (time and costs) factors likely
to influence intention and adherence to TB evaluation
guidelines. To inform the design of the intervention,
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identified barriers were prioritized in consultation with
key stakeholders and then organized into three categor-
ies using the PRECEDE model: (1) predisposing factors—
prior motives that either support or inhibit behavior, (2)
reinforcing factors—rewards or punishments following a
behavior or anticipated as a consequence of it, and (3)
enabling factors—objective characteristics of an individ-
ual or environment that facilitate behavior [19]. The
intervention strategy was developed to address each of
these factors through the following components:
1) Onsite molecular testing using GeneXpert Edge:
Patients presenting to health centers in the
intervention strategy arm have access to rapid
Xpert testing as a first-line TB test to target key
predisposing (health worker time and workload
constraints) and enabling (low sensitivity of
sputum smear microscopy and inconsistent/delayed
specimen transport to Xpert testing sites) factors.
The trial began with intervention sites receiving
a modified (external battery and dust filter)
conventional one-module GeneXpert instrument
(GeneXpert I), which was replaced with a Gen-
eXpert Edge instrument once it became available
in the third quarter of 2019.
2) Process re-design to facilitate same-day TB
diagnosis and treatment: A standardized checklist
was used to re-organize staff and patient workflow at
intervention sites as an enabling factor to address the
failure of patients to return after the initial health
center visit. The process re-design focuses on
ensuring that (1) TB screening was conducted at
all clinic entry points using NTLP-mandated
active case finding forms, (2) patients who
screen positive were rapidly referred to the
laboratory for sputum collection and testing,
and (3) positive test results were reported
immediately to patients and clinicians. Summaries of
specific process changes made at each site are
available in Additional file 1.
3) Performance feedback: Intervention strategy sites
receive a monthly report card that includes site-
specific TB diagnostic evaluation quality indicators
as well as indicators averaged across all intervention
strategy sites as a reinforcing factor to address the
lack of communication between staff and limited
oversight from district TB supervisors. Upon receipt
of the report card, health center staff (along with
the district TB supervisor when present) were
required to identify barriers to improvement and
Fig. 1 Theory-informed barrier assessment and design of intervention strategy
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develop plans to improve site performance follow-
ing a Plan-Do-Study-Act model.
Health center recruitment
A list of eligible health centers (i.e., clusters) that
expressed interest in participating in the trial was
reviewed with the Uganda NTLP and the National
Tuberculosis Reference Laboratory (NTRL) Directors.
Research staff met with the District Health Officer
(DHO) for each approved site to inform him or her
about the study and requested the participation of
the site. If the request was granted, the DHO was asked
to sign a Memorandum of Understanding describing key
study procedures and expectations of participating sites.
Study staff scheduled an enrollment visit with approved
trial sites and followed a standard script to present the
project to health center staff, including project aims and
procedures. The final list of 20 sites to be randomized
was selected from among sites deemed to be eligible, in
consultation with the trial statistician to minimize po-
tential for site-level variation that could impact power.
Randomization
Participating health centers were grouped into two
equal-sized strata based on the proportion of patients
with microbiologically confirmed TB initiated on treatment
within 2 weeks of initial presentation at the health center in
the year prior to the start of the trial. Stratification was used
to help reduce between-cluster variation and enhance base-
line balance with respect to the number of patients evalu-
ated for and diagnosed with TB between arms. Site- and
patient-level baseline characteristics strongly correlated
with the proportion of microbiologically confirmed TB
were identified; these included health center region, health
center size, and HIV prevalence among TB patients. Re-
striction, a common approach in cluster-randomized trials
with a small number of clusters, was used to help achieve
baseline balance of these important site- and patient-level
characteristics. The restriction factor was calculated, and
the validity of the restriction was assessed using the validity
matrix [20]. Random allocation sequences meeting stratifi-
cation and restriction criteria were generated in STATA 14,
resulting in 11,392 randomizations (StataCorp LP, College
Station, TX). For convenience, 10,000 randomizations were
randomly selected and each assigned a unique four-digit
sequence (0000–9999). Health center representatives and
district health officials were invited to participate in a
randomization ceremony chaired by the Uganda NTLP
Director. During the ceremony, four health center repre-
sentatives were each requested to draw from a bag contain-
ing soccer balls numbered 0–9 to select the trial
randomization sequence. The Uganda NTRL Director was
then invited to select a final ball which determined the
intervention strategy arm assignment based on being an
odd or even number (Fig. 2).
Blinding
Blinding of arm assignment is not feasible due to the na-
ture of the intervention strategy. Investigators and study
staff, with the exception of the trial statistician and data
manager, are masked to ongoing aggregated patient-level
data by study arm.
Data collection and management
Patient-level data to assess processes of TB care are ab-
stracted from routine data sources at trial sites and
Xpert testing hubs (for control sites) for all eligible pa-
tients and entered into Research Electronic Data Cap-
ture (REDCap), a secure web-based application used for
data collection and management in clinical research [21,
22]. Routine source documents include NTLP TB regis-
ters (presumptive, laboratory, and treatment registers),
Xpert referral forms, and test data from GeneXpert de-
vices. The procedures for patient-level data collection
have been described in an earlier publication [5]. Briefly,
health center staff not involved in TB diagnosis or treat-
ment capture photos of source documents on password-
protected smartphones and upload the photos to a se-
cure central server every 2 weeks. Upon receipt, study
staff review photos for completeness and accuracy, and
attempts are made to address missing or conflicting data
with health clinic staff. Study staff then abstract individ-
ual patient-level data on demographics, HIV and ART
status, and TB testing from photos and enter the data
into a password-protected REDCap study database. Data
cleaning is performed regularly to identify missing or in-
consistent information, and study staff resolve data quer-
ies during quarterly site visits through discussion with
health center staff, review of primary data sources, and
review of additional data sources (e.g., clinic registration
book, ART register).
Patient-level data to assess health outcomes (vital sta-
tus) are collected through a combination of patient
phone calls and home visits. Phone calls and home visits
are conducted between 6 and 8months after patients
initiate TB diagnostic evaluation.
Patient-level process and health outcome data collection
is supplemented by focused data collection to assess imple-
mentation (fidelity and acceptability) (Table 1). Process
metrics that reflect adoption of and fidelity to each compo-
nent of the intervention strategy are assessed throughout
the post-randomization period using test data downloaded
quarterly from GeneXpert devices and performance feed-
back reports retrieved during quarterly site visits. Focus
group discussions with health workers involved in TB diag-
nostic evaluation at each intervention strategy site are held
at least 12months after randomization to assess the
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Table 1 Mixed methods evaluation strategy, sample, goal, data collection timing, and analysis
Strategy Sample Goal Data collection Analysis
Process metrics All patients referred for TB
diagnostic evaluation at
intervention sites
Examine variability in adoption
of and fidelity to intervention
components across sites
Entire post-randomization
period
Multivariate regression
models
Surveys 1) Health workers involved
in TB evaluation at all sites*
2) Sixty patients per site
(20 patients/site, 400 total
pre-randomization; 40 patients/site,
800 total post-randomization)**
Examine whether the XPEL
TB strategy modifies targeted
barriers to TB diagnostic
evaluation
Once before and once after
trial is completed
Multivariate regression
models
Focus groups Health workers involved in
TB evaluation at intervention sites*
Assess acceptability of each
component of the intervention
strategy.
After trial is completed Thematic interpretation
In-depth interviews Purposive: 20–30 health
workers at high- and low-
performing intervention strategy
sites (2–3/site)
Understand reasons for variability
in adoption and implementation
of the XPEL TB strategy
After trial is completed Thematic interpretation
*Based on prior experience, we anticipate 5–10 staff members will be involved in TB diagnostic services at each health center (50–100 each at intervention and
control health centers)
**Patients will be selected randomly within strata based on gender and timing of health center visit (undergoing TB testing vs. completed testing/initiating
TB treatment)
Fig. 2 Site selection and enrollment for XPEL TB trial
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acceptability of each intervention strategy component.
Surveys with health workers (assessing theory of
planned behavior constructs knowledge, attitudes, sub-
jective norms, and self-efficacy related to TB diagnostic
evaluation guidelines) and patients (assessing direct and
indirect costs of and satisfaction with TB diagnostic
evaluation) are conducted at all sites pre-randomization
and at least 12 months after randomization to evaluate
whether the intervention strategy modifies targeted bar-
riers to TB diagnostic evaluation (see Fig. 1/Table 1).
The surveys are conducted using validated patient cost
and satisfaction with care questionnaires adapted to the
local context [23, 24]. Last, in-depth interviews are
conducted with health workers at high- and low-
performing sites (based on analysis of patient-level,
process metric, focus group, and survey data) after the
trial is completed to better understand reasons for vari-
ability in adoption and implementation of the interven-
tion strategy.
Health economic data collection includes detailed
budgetary analysis, interviews with key staff members,
review of logbooks and/or timesheets to record propor-
tions of staff time devoted to various activities, and
time-and-motion studies of health workers involved in
TB diagnostic evaluation.
Trial outcomes
Trial outcomes were developed to address the five do-
mains of the RE-AIM implementation research frame-
work: depth of reach into a target population, effectiveness
in closing gaps along the TB diagnostic evaluation cascade
of care and improving health outcomes, factors that pro-
mote adoption, fidelity and costs of implementation, and
factors that ensure maintenance over time (Table 2) [25].
The primary outcome reflects completion of the process
of TB diagnostic evaluation and was originally the propor-
tion of patients diagnosed with and treated for TB within
14 days. However, due to unexpected increases in the
number of patients being tested for TB at intervention
sites during the first 6 months of the trial, the Trial Steer-
ing Committee approved changing the primary outcome
from a proportion to the absolute number diagnosed with
and treated for TB within 14 days. Details on the rationale
for and implications of changing the primary outcome
from a proportion to a count are described in Additional
file 2. Additional outcomes by RE-AIM domain are pre-
sented in Table 2.
Sample size and power considerations
The number of trial sites was chosen based on feasibility
considerations. The number of participants and resulting
Table 2 Trial outcomes categorized using the RE-AIM framework
RE-AIM domains Trial outcomes
Reach • Number/proportion completing Xpert testing
Effectiveness Process outcomes
• Number/proportion diagnosed with and treated for TB within 14 days
• Number/proportion diagnosed with microbiologically-confirmed TB
• Time to diagnosis of microbiologically-confirmed TB
• Number/proportion diagnosed with rifampin resistance
• Number/proportion with microbiologically-confirmed TB completing treatment
Health and health economic outcomes
• Number/proportion who died within 6 months
• Number/proportion with microbiologically-confirmed TB who died within 6 months
• Number/proportion treated for TB who died within 6 months
• Incremental cost-effectiveness ratio
Adoption • Proportion of eligible sites able and willing to initiate each component of the intervention strategy
Implementation Fidelity
• Process metrics for each intervention strategy component
• Proportion tested by Xpert
• Number of GeneXpert device non-operation days
• Proportion of invalid, error, or indeterminate Xpert results
• Proportion treated on same-day if Xpert-positive
• Proportion of performance feedback report cards reviewed at staff meetings
• Qualitative data from health worker focus group discussions and in-depth interviews
Acceptability
• Thematic output from health worker focus group discussions
Patient and health system costs
• Incremental cost of introducing and maintaining the intervention strategy
• Incremental patient cost per diagnostic evaluation and per treatment initiated
Modification of targeted barriers
• Median scores for health worker knowledge, attitudes, subjective norms, and self-efficacy related to
TB diagnostic evaluation guidelines
• Thematic output from provider in-depth interviews
• Median patient costs associated with completing TB diagnostic evaluation
• Median scores for domains of patient satisfaction questionnaire
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trial duration were chosen using the proportion of pa-
tients diagnosed with and treated for TB within 14 days
as the primary outcome. Sample size calculations appro-
priate for cluster-randomized trials used the following
assumptions: 10 clinics per trial arm, an 18-month trial
duration, a type I error of 5%, and a power of 90% [20].
Pre-randomization data collected from the 20 trial sites
between January and December 2017 showed that 6.7%
of patients referred for TB evaluation were initiated on
treatment for confirmed TB within 2 weeks, with a 0.36
coefficient of variation (k) between clusters and a har-
monic mean of 268 eligible patients enrolled at each
health center (cluster). Based on these conditions and
allowing for 10% missing data, an 18-month trial dur-
ation was chosen to achieve a target sample size of 5360
patients. Power and detectable effect size calculations
were repeated when the primary outcome was approved
for change from a proportion to a count. Using the same
trial parameters (10 clinics per trial arm, 18-month trial
duration, and a mean of 268 patients per cluster) and as-
suming a 0.2–0.3 within-arm standard deviation of the
log-transformed outcome based on pre-trial data, the
trial has 80–90% power to detect a geometric mean ratio
in the number of TB cases diagnosed and treated within
14 days of 1.30–1.58, comparing the intervention and
control arms. This range of detectable effect sizes is rea-
sonable given that Xpert MTB/RIF is twice as sensitive
as smear microscopy (i.e., double the number of con-
firmed TB cases), and onsite testing is expected to re-
duce pre-treatment loss to follow-up by at least half
(from 30 to < 15%).
The sample size for nested studies is either fixed by
parameters of the clinical trial (process metrics, provider
surveys, and provider focus groups) or based on feasibil-
ity considerations (patient surveys and provider in-depth
interviews). For quantitative analyses, the sample size is
sufficiently large (data on approximately 11,283 patients
and 180 performance feedback reports for process met-
rics, 800 patient surveys, and 100–200 provider surveys)
to enable multivariable analysis to identify factors associ-
ated with adoption and implementation of the interven-
tion strategy.
Analysis
Analysis of the primary outcome
The primary analysis will be conducted at the cluster
(clinic)-level. Poisson regression or negative binomial re-
gression will be used, depending on whether there is evi-
dence for over-dispersion. An offset at the clinic level
representing days contributing patients to the study will
be applied if any trial site unexpectedly withdraws from
the study. The model will adjust for randomization
strata and the count of microbiologically confirmed TB
cases initiated on treatment within 14 days in the 12-
month period before the trial start date.
Analysis of implementation outcomes
A cluster-level analysis will be performed to compare
the change from baseline (pre-randomization) to post-
intervention in patient cost, patient satisfaction with
care, and health worker beliefs about TB diagnostic
evaluation guidelines. Identification of patient-, pro-
vider-, and/or clinic-level factors associated with
the adoption and implementation of intervention com-
ponents (as determined by process metrics) will be done
through linear or logistic regression.
Qualitative analyses will involve collaborative develop-
ment of a coding framework and detailed coding of tran-
scripts using the qualitative software analysis program
Dedoose [26]. Coded transcripts will be sorted to iden-
tify thematic groupings. Thematic interpretation will
focus on the individual, social, and structural factors as-
sociated with successful or unsuccessful adoption and/or
implementation of the intervention components at dif-
ferent sites.
Trial rollout
After enrollment into the study, a visit was made to each
trial site and affiliated Xpert testing hub (for control
sites) to assess the completeness of TB register data and
conduct refresher trainings on Uganda NTLP guidelines
(trial sites) or GeneXpert device maintenance and oper-
ation (Xpert testing hubs). At each site, baseline data
were collected for the 12-month period prior to the
planned trial start date to facilitate stratified and re-
stricted randomization.
In the 3 months prior to the planned trial start date, a
2-day site visit was made to each trial site. At control
sites, key messages related to TB guidelines were re-
emphasized, including processes for referral of sputum
samples for Xpert testing. Laboratory staff received re-
fresher training on sputum collection and sputum smear
microscopy, including proficiency testing using panel
slides. Laboratory and drug inventories were reviewed to
ensure adequate supply of sputum collection cups, glass
slides, staining reagents, and TB drugs. Completeness of
TB laboratory and treatment registers was assessed, and
re-training provided as needed. Guidelines refresher and
TB register completion trainings were also provided at
the intervention sites. Additionally, at intervention sites,
a GeneXpert I device, battery, and solar panel were in-
stalled, and laboratory staff were trained on sputum col-
lection, Xpert testing, documentation, and device
maintenance. Laboratory and clinical staff were trained
on interpretation of Xpert results. Health center staff
were engaged in a discussion about laboratory, clinical,
and pharmacy workflow reorientation, with an emphasis
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on prompt identification and referral of patients with
possible active TB for sputum collection, onsite molecu-
lar testing, communication of diagnostic results to clini-
cians, and same-day treatment initiation for Xpert-
positive patients. Finally, all staff were introduced to per-
formance feedback report cards and given expectations
for review and follow-up actions.
Research staff visit all trial sites quarterly to resolve
missing data queries, collect health system cost data, and
conduct provider surveys and focus group discussions.
In addition, a report card is generated for intervention
sites for distribution each month. Upon receipt of the re-
port card, sites complete an attached worksheet to de-
scribe any barriers to performance, as well as goals to
improve performance. No further follow-up is done with
these report cards and/or worksheets. All other contact
between research staff and health center staff is kept
minimal.
Discussion
Novel TB diagnostic tests such as onsite Xpert testing
have the potential to minimize attrition along the TB
care cascade and thereby improve rates of TB diagnosis
and treatment. Evaluation of these tests and associated
implementation strategies should be conducted within
settings and populations of intended use to demonstrate
their expected impact after scale-up. However, trial
design and execution features—even for those labeled as
pragmatic—have often utilized resources or procedures
that are not available in routine care and exclude key pa-
tient sub-populations [27]. These design choices can re-
duce attrition along the TB diagnostic cascade of care in
both trial arms, affecting the ability of a trial to demon-
strate the impact of novel TB diagnostic tests and strat-
egies relative to what might occur in usual care.
The XPEL-TB trial combines an ultra-pragmatic ap-
proach to implementation with a hybrid type II design
to (1) demonstrate the expected impact of onsite Xpert
testing on patient-important outcomes and (2) explain
why and how the intervention strategy based around
onsite Xpert testing did or did not work. The ultra-
pragmatic approach minimizes the impact of trial proce-
dures on routine care practice, limiting the potential im-
pact on key primary and secondary outcomes. This is
particularly noteworthy in the context of previous TB
diagnostic studies, which were either implemented in
specialized settings (e.g., tertiary health centers) or used
resources and/or procedures not available in routine
care such as on-site research staff, additional diagnostic
testing (chest X-ray and culture), or financial incentives
to minimize patient loss to follow-up [28–30]. Addition-
ally, narrowly defined inclusion criteria as commonly
seen in many TB diagnostic trials can restrict enrollment
to patients with a higher pre-test probability of TB or
Table 3 XPEL-TB PRECIS-2 domains
PRECIS-2 domain Assessment of XPEL-TB Rating (1–5, where 5 is very pragmatic)
Eligibility Nearly all adults who would have been offered Xpert testing if
available in routine care are included in the trial. Only patients
with a previous history of TB are excluded (to not falsely increase
the primary outcome).
5
Recruitment No formal recruitment procedures are used. A waiver of consent
was obtained to enable automatic inclusion of data on all adults
undergoing TB evaluation at trial sites. No incentives given to
patients in either arm.
5
Setting The trial is implemented at 20 sites at the lowest level of the
health system where TB diagnostic services (sputum smear microscopy)
are provided—the sites targeted for expansion of Xpert testing
using next-generation platforms.
5
Organization Xpert testing is implemented using existing healthcare staff and
infrastructure at trial sites.
5
Flexibility: delivery Process re-design and performance feedback were adapted by
each trial site to suit its needs and processes of care and supervision.
5
Flexibility: adherence No additional incentives or procedures are in place to encourage
patients in the intervention arm with microbiologically-confirmed
TB to initiate on treatment.
5
Follow-up Process and outcome data are collected from routine clinic records.
No onsite research staff to conduct patient enrollment, data collection,
or follow-up, with the exception of vital status assessment.
5
Primary outcome The primary outcome is relevant to TB patients, their relatives, clinic
staff, and the Uganda NTLP
5
Primary analysis No special allowances will be made in the primary analysis for
non-adherence or variability in implementation by site
5
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patients more likely to comply with follow-up. These
features are likely to improve outcomes in both trial
arms, making it difficult to assess the true impact of the
intervention. Thus, each design element of the XPEL-TB
trial was oriented towards the ultra-pragmatic end (score
of 5) of the pragmatic-explanatory continuum, per
scores generated using the PRECIS-2 tool (Table 3) [16].
To the best of our knowledge, this is among the first TB
diagnostic trials that does not involve formal recruitment
and consent procedures and uses data abstracted from
routine data sources to assess the primary and key sec-
ondary outcomes.
A hybrid type II effectiveness-implementation design
was selected to facilitate concurrent evaluation of the
clinical effectiveness and implementation of onsite Xpert
testing. The dual focus on effectiveness and implementa-
tion is innovative in global health diagnostics. Previous
trials of Xpert testing have not included co-interventions
to support implementation and were designed primarily
to evaluate effectiveness, with minimal attention given to
why and how Xpert testing did or did not work [31].
Such information is critical to guide scale-up efforts in
Uganda and in other settings.
It is expected our trial design and implementation ap-
proach will influence our findings, as well as inform next
steps for clinical practice and research. We anticipate
that implementation under real-world conditions will
help demonstrate an increase in the number of patients
diagnosed and treated for active pulmonary TB within 2
weeks of initial presentation at the health center. If in-
deed the case, this finding would diverge from most
published data on the effectiveness of Xpert testing on
patient-important outcomes, such as mortality, and
could result in more support and funding for GeneXpert
scale-up worldwide. In addition, qualitative data on fidel-
ity of implementation, barriers to uptake, and variability
of uptake as well as data on cost and cost-effectiveness
will inform modifications to intervention components
beyond the conclusion of the trial.
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